US Epigenetics Market (2025-2030)
The US Epigenetics Market was valued at $505.9 Million in 2025 and projected to reach to $960.1 Million by 2030, representing a compound annual growth rate of 13.7%. The US epigenetics market is positioned for sustained expansion through 2030, driven by increasing healthcare provider adoption of epigenetic testing and personalized medicine approaches.
US Epigenetics Market Trends and Insights
- This expansion reflects the US healthcare sector's increasing investment in precision medicine and personalized treatment approaches.
- The US market benefits from advanced research infrastructure, substantial pharmaceutical R&D spending, and growing clinical adoption of epigenetic biomarkers across oncology, cardiovascular, and neurological applications. Driving this growth, the US is witnessing heightened demand for epigenetic diagnostics and therapeutics as healthcare providers recognize the potential to improve patient outcomes through gene expression modulation.
- The US regulatory environment, supported by FDA initiatives on precision medicine, continues to facilitate the development and commercialization of epigenetic-based solutions.
- Between 2025 and 2030, the US market will be shaped by increasing collaboration between academic institutions, biotech firms, and pharmaceutical companies focused on translating epigenetic discoveries into clinical practice..
Key Market Statistics
- CAGR (2025-2030) 13.7% CAGR
- Market Size, 2025 ~USD 505.9 Million
- Forecast, 2030 ~USD 960.1 Million
- Country US
US Epigenetics Market Overview
Market Valuation Growth :
The US epigenetics market is valued at $505.9 million in 2025 and is projected to reach $960.1 million by 2030, representing a robust 13.7% CAGR driven by precision medicine adoption.
Advanced Research Infrastructure :
The US benefits from world-leading research institutions, FDA regulatory frameworks, and substantial pharmaceutical R&D investments that accelerate epigenetics innovation and commercialization.
Precision Medicine Integration :
US healthcare providers are increasingly integrating epigenetic testing into personalized treatment protocols, improving patient outcomes across oncology, cardiovascular, and neurological applications.
Clinical Application Expansion :
Growing clinical adoption of epigenetic biomarkers for disease diagnosis, prognosis, and treatment selection is expanding market opportunities across major US healthcare systems and specialty clinics.
US Epigenetics Market Dynamics
- Major pharmaceutical companies and biotech firms are investing heavily in epigenetic drug development, with several candidates in clinical trials targeting cancer, neurological disorders, and metabolic diseases.
- Regulatory support from the FDA and reimbursement improvements are expected to accelerate market penetration across hospital networks and diagnostic laboratories.
- The convergence of genomic sequencing technologies, artificial intelligence, and clinical evidence will further validate epigenetic applications in precision oncology and preventive medicine.
- US market growth will outpace global averages as healthcare systems prioritize personalized treatment strategies and value-based care models..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Qiagen N.V.
- Agilent Technologies, Inc.
- Danaher Corporation
Key Takeaways
- The US epigenetics market is valued at $505.9 million in 2025 and will nearly double to $960.1 million by 2030, representing a 13.7% CAGR.
- The US leads in epigenetic research funding and clinical adoption, driven by precision medicine initiatives and FDA regulatory support.
- US healthcare providers are increasingly integrating epigenetic biomarkers into oncology, cardiovascular, and neurological treatment protocols.
- The US market growth is fueled by partnerships between academic institutions, biotech companies, and pharmaceutical firms advancing epigenetic therapeutics.
Epigenetics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | HISTONES (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 13.9% from 2025 to 2030 |
| Largest Segment | KITS & REAGENTS (Offering) |
| Market Size Base Year (Billions) | ~USD 2.24 (2025) |
| Revenue Forecast (Billions) | ~USD 4.29 (2030) |
| Segments Covered | Offering, Type, Technology, Method, Application, End User |
US Epigenetics Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Enzymes
- Instruments & Accessories
- Kits & Reagents
- Product
- Products
- Services
- Software
By Type
- 5-Hmc & 5-Mc Analysis Kits & Reagents
- Antibodies
- Bisulfite Conversion Kits & Reagents
- Chip-Sequencing Kits & Reagents
- Dna-Modifying Enzymes
- Enzymes
- Histones
- Instruments & Accessories
- Kits & Reagents
- Other Enzymes
- Other Kits & Reagents
- Protein-Modifying Enzymes
- Services
- Software
- Whole-Genome Amplification Kits & Reagents
By Technology
- Mass Spectrometry
- Next-Generation Sequencing (Ngs)
- Ngs
- Other Techniques
- Other Technologies
- Pcr & Qpcr
- Sonication
By Method
- Dna Methylation
- Histone Modifications
- Other Methods
By Application
- Cardiovascular Diseases
- Developmental Biology
- Immunology
- Metabolic Diseases
- Oncology
- Other Applications
By End User
- Academic & Research Institutes
- Contract Research Organization
- Contract Research Organizations
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
Target Audience
- Pharmaceutical & Biotech Companies : Need US market sizing and growth forecasts to guide epigenetic drug development pipelines, clinical trial planning, and commercialization strategies for precision medicine products.
- Diagnostic Laboratory Providers : Require market data on epigenetic testing adoption rates, reimbursement landscapes, and clinical demand drivers to expand service offerings and capture market share in US healthcare systems.
- Healthcare Investment Firms : Seek detailed US market analysis to evaluate investment opportunities in epigenetics companies, assess portfolio company growth potential, and identify emerging market trends and consolidation targets.
- Hospital & Healthcare Systems : Need insights on epigenetic testing integration, clinical evidence, and patient outcomes to inform procurement decisions, precision medicine program development, and competitive positioning.
- Medical Device & Technology Companies : Require US market intelligence on epigenetic sequencing platforms, data analytics tools, and clinical workflow integration opportunities to develop complementary solutions and expand market presence.
Key Companies in the US Epigenetics Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| APEX BIOTECHNOLOGY CORP. | Taiwan | Public Company | Blood glucose monitoring systems (meters and strips),Other biosensor-based analyte systems (uric acid, cholesterol, lactate, HbA1c, ketone, coagulation, multifunction),Pesticide residue check systems, |
| BIOGEN | United States | Public Company | Multiple Sclerosis therapies (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS economics),Spinal muscular atrophy and rare neuromuscular (SPINRAZA, QALSODY),Alzheimer’s and neurodegeneration (LEQEMBI, related), |
| EPIZYME | United States | Private Company | Tazemetostat – approved indications (epithelioid sarcoma, select lymphomas),Tazemetostat – pipeline/label-expansion use (INI1-negative tumors, combinations),Other pipeline (PRMT5 inhibitor, PRMT1 inhibitor, PARP-combination programs), |
| SIGMA-ALDRICH CORPORATION | United States | Private Company | Life science reagents and biochemicals,Cell culture media and pharma/biopharma manufacturing consumables,Analytical chemistry, filtration, and labware, |
| TRANSGENOMIC, INC. | United States | Public Company | Oncology and pharmacogenomics testing services,Multiplexed ICE COLD-PCR reagents,Other genomic testing and research services, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array-based instruments and consumables, |
| MERCK KGAA | Germany | Public Company | Life Science (research reagents, lab consumables, bioprocessing and CDMO services),Electronics (semiconductor materials, specialty gases, delivery equipment, display and OLED materials),Healthcare (oncology, neurology, immunology, fertility, rare disease therapies), |
| PACBIO | United States | Public Company | Long-read sequencing instruments (Revio, Sequel, Vega),Long-read consumables and SMRT reagents,Short-read sequencing (Onso) and related consumables, |
| DANAHER | United States | Public Company | Biotechnology (bioprocessing and related solutions),Life Sciences (instruments, genomics, and analytical tools),Diagnostics (clinical instruments and consumables), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics systems, kits, and quality controls,Life Science instruments and systems,Life Science reagents and consumables, |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and infectious disease assays,Oncology and sexual & reproductive health assays, |
| REVVITY | United States | Public Company | Diagnostics instruments, reagents, and assay platforms,Life science reagents, antibodies, and genomic tools,Instruments, imaging, software, and services, |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, virology, vaginitis, SARS-CoV-2),Breast Health (3D mammography, biopsy, markers, localization, software, service),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa ProVu, CoolSeal), |
APEX BIOTECHNOLOGY CORP.
APEX Biotechnology Corp. is a public company based in Taiwan that was founded in 1997.
BIOGEN
BIOGEN is a United States-based public biotechnology company founded in 1978 with 7,500 employees.
EPIZYME
EPIZYME is a United States-based private company founded in 2007 with 250 employees.
SIGMA-ALDRICH CORPORATION
SIGMA-ALDRICH CORPORATION is a United States-based private company founded in 1951 with 9,800 employees.
TRANSGENOMIC, INC.
TRANSGENOMIC, INC. is a United States-based public company founded in 1997 with 19 employees.
THERMO FISHER SCIENTIFIC INC.
THERMO FISHER SCIENTIFIC INC. is a United States-based public company founded in 1956 with 125,000 employees.
ILLUMINA, INC.
ILLUMINA, INC. is a United States-based public company founded in 1998 with 8,625 employees.
MERCK KGAA
MERCK KGAA is a German public company founded in 1668 with 59,077 employees.
PACBIO
PACBIO is a United States-based public company founded in 2000 with 485 employees.
DANAHER
DANAHER is a United States-based public company founded in 1969 with 59,000 employees.
BIO-RAD LABORATORIES, INC.
BIO-RAD LABORATORIES, INC. is a United States-based public company founded in 1952 with 7,450 employees.
QIAGEN
QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees.
REVVITY
REVVITY is a United States-based public company founded in 1937 with 11,000 employees.
HOLOGIC, INC.
HOLOGIC, INC. is a United States-based private company founded in 1985 with 7,070 employees.
Reasons to Buy this Report
- Market Size & Growth Validation : Quantified US market data with precise valuations ($505.9M in 2025) and 5-year forecasts enable accurate financial planning, investment decisions, and revenue projections for stakeholders.
- Competitive Landscape Intelligence : Understand US-specific market dynamics, key players, and competitive positioning to identify partnership opportunities, acquisition targets, and differentiation strategies in the precision medicine space.
- Clinical & Regulatory Insights : Access detailed analysis of FDA approval pathways, reimbursement trends, and clinical adoption rates specific to the US market to accelerate product commercialization and market entry strategies.
- Investment & Funding Opportunities : Identify high-growth segments, emerging applications, and underserved clinical areas within the US epigenetics market to guide venture capital allocation and strategic R&D investments.
- Strategic Market Positioning : Leverage US-specific market trends, healthcare system requirements, and patient demographics to develop targeted go-to-market strategies and optimize resource allocation for maximum ROI.
Frequently asked questions
What is the current size of the US epigenetics market?
The US epigenetics market is valued at $505.9 million in 2025 and is expected to reach $960.1 million by 2030.
What is the projected growth rate for the US epigenetics market?
The US epigenetics market is projected to grow at a compound annual growth rate (CAGR) of 13.7% from 2025 to 2030.
Which therapeutic areas are driving growth in the US epigenetics market?
Oncology, cardiovascular disease, and neurological disorders are the primary therapeutic areas driving epigenetic market expansion in the US.
How is the US regulatory environment supporting epigenetics market growth?
The US FDA's precision medicine initiatives and supportive regulatory pathways are facilitating the development and commercialization of epigenetic-based diagnostics and therapeutics.
What factors are contributing to the US epigenetics market expansion?
Key factors include increased R&D investment, growing clinical adoption of epigenetic biomarkers, academic-industry collaborations, and rising demand for personalized medicine solutions in the US.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global epigenetics market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the epigenetics market. The secondary sources used for this study include World Health Organization (WHO), World Intellectual Property Organization (WIPO), International Union of Biochemistry and Molecular Biology (IUBMB), National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), Centers for Disease Control and Prevention (CDC), American Cancer Society (ACS), American Society for Biochemistry and Molecular Biology (ASBMB), Canadian Society for Molecular Biosciences (CSMB), National Institute of Environmental Health Sciences (NIEHS), Canadian Institutes of Health Research (CIHR), Genome Canada, and Central Drugs Standard Control Organisation (CDSCO). Academic Journals and Company Websites, corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations, among others. Secondary data were collected and analyzed to determine the overall size of the global epigenetics market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
Note: Tier 1 companies’ revenue is more than USD 10 billion; Tier 2 companies’ revenue ranges between USD 1 and 10 billion; and Tier 3 companies’ revenue ranges between USD 500 million and USD 1 billion
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the epigenetics market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
The epigenetics market is defined as the use of products such as reagents & kits, instruments and software for isolation/extraction, target enrichment, amplification/library preparation, sequencing/profiling and bioinformatics & data analysis of epigenetic biomarkers and samples (biological samples such as liquid biopsy samples, tissue samples and nucleic acid & protein isolates). The report scope is inclusive of outsourcing services such as DNA methylation services, chromatin profiling services, and single-cell/multi-omics services, among others. These products & services applied in drug discovery & development (oncology, metabolic disorders, immunology, cardiovascular diseases), and research (developmental biology) are covered in the report scope.
Key Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Contract development and manufacturing organizations (CDMOs)
- Life science companies
- Academic & research institutes
- Private research institutes
- Venture capitalists & investors
- Market research & consulting firms
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the epigenetics market based on offering, product, service, technology, method, application, end user (product), end user (service), and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall epigenetics market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the epigenetics market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the epigenetics market
- To benchmark players within the epigenetics market using the ‘Company Evaluation Matrix’ framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Geographical Analysis
- Further breakdown of the Rest of Europe epigenetics market, by country
- Further breakdown of the Rest of Asia Pacific epigenetics market, by country
- Further breakdown of the Rest of Latin America epigenetics market, by country
- Further breakdown of the Rest of Middle East epigenetics market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Get the Full Epigenetics Market Report
Full forecast, segment splits, and company analysis for all Epigenetics Market.
- Canada Epigenetics Market
- Germany Epigenetics Market
- UK Epigenetics Market
- France Epigenetics Market
- Italy Epigenetics Market
- Spain Epigenetics Market
- China Epigenetics Market
- Japan Epigenetics Market
- India Epigenetics Market
- Australia Epigenetics Market
- South Korea Epigenetics Market
- Brazil Epigenetics Market
- Mexico Epigenetics Market
- Saudi Arabia Epigenetics Market
- UAE Epigenetics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report